Roche aims for derisked deals and ruthless portfolio cuts in 2025

Elizabeth Cairns

Senior biopharma journalist

Roche’s M&A strategy in the coming year revolves around derisked mechanisms and high unmet needs, CEO Thomas Schinecker said Thursday. And further dealmaking over assets …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche aims for derisked deals and ruthless portfolio cuts in 2025

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Trump’s science crackdown hits rare disease research: ‘We need to sit down with Elon Musk’

At least seven drugmakers say they will participate in round two of IRA negotiations

Exclusive: Infectious disease doctors consider 'mini-ACIP' if RFK erodes CDC vaccine panel

Lilly joins molecular glue field with Magnet deal worth up to $1.25B

Where the money is: The top 100 venture investors in biotech

How AI can address ongoing challenges in the life sciences industry

Roche aims for de­risked deals and ruth­less port­fo­lio cuts in 2025

Senior biopharma journalist

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Roche aims for derisked deals and ruthless portfolio cuts in 2025